Mounjaro: What It Is, How It Works, and How It Compares to Wegovy, Ozempic, Zepbound, and Saxenda

What Is Mounjaro and What Is It Approved For?

Mounjaro is the brand name for tirzepatide manufactured by Eli Lilly. The FDA granted approval in May 2022 specifically for glycemic control in adults with type 2 diabetes, used alongside diet and exercise. Unlike every other drug in the GLP-1 class, tirzepatide is a dual agonist: it activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor at the same time.

The GIP component is the differentiating factor. GIP is an incretin hormone that increases insulin secretion after meals and may also act directly on adipose tissue and the central nervous system to reduce food intake. Adding GIP agonism on top of GLP-1 agonism appears to produce additive effects on body weight and blood glucose that single-receptor drugs cannot replicate with the same consistency.

Zepbound, approved in November 2023, is the same tirzepatide molecule repackaged under a different brand name specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea. Mounjaro is frequently prescribed off-label for weight loss, though insurers often cover Zepbound more predictably for that indication.

The FDA label for Zepbound carries the same boxed warning as Mounjaro: do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). [1]

How Tirzepatide Works: The Dual GIP/GLP-1 Mechanism

GLP-1 receptor agonists such as semaglutide and liraglutide slow gastric emptying, suppress glucagon, stimulate insulin release in a glucose-dependent manner, and reduce appetite through hypothalamic signaling. Tirzepatide does all of that. It also binds GIP receptors, which are expressed in the pancreas, brain, bone, fat, and gut.

Preclinical research suggested GIP agonism might oppose weight loss, but the human data reversed that hypothesis. In SURMOUNT-1 (N=2,539, non-diabetic adults with obesity), all three tirzepatide doses beat placebo by a large margin. At 72 weeks, the 5 mg dose produced 15.0% mean weight loss, the 10 mg dose produced 19.5%, and the 15 mg dose produced 20.9%, compared with 3.1% in the placebo group (P<0.001 for all doses vs. placebo). [2]

The hypothesized reason for tirzepatide's superior performance over GLP-1-only agents is that GIP receptors in the hypothalamus amplify the satiety signal beyond what GLP-1 alone achieves. GIP may also improve energy expenditure by acting on brown adipose tissue, although the precise magnitude of that contribution in humans is still being quantified.

SURMOUNT Clinical Trial Program: What the Data Actually Show

The SURMOUNT program is tirzepatide's weight-management trial series, separate from the SURPASS diabetes program. Four completed trials are especially relevant for patients weighing Mounjaro or Zepbound against competing drugs.

SURMOUNT-1 (N=2,539 to 72 weeks) enrolled adults without diabetes who had obesity or overweight with comorbidities. The 15 mg tirzepatide group lost 20.9% of body weight, and 63% of participants in that group lost at least 20% of baseline weight. [2] No GLP-1-only drug has replicated that 20% threshold at the population level in a phase 3 trial.

SURMOUNT-2 (N=938 to 72 weeks) enrolled adults with type 2 diabetes. Tirzepatide 15 mg produced 15.7% weight loss versus 3.3% for placebo, and HbA1c dropped by 2.01 percentage points in the 15 mg group. [3] These are numbers that matter for a drug whose primary approval is glycemic control.

SURMOUNT-3 (N=579) tested tirzepatide after a 12-week intensive lifestyle intervention lead-in, a design meant to show what happens when medication is layered onto already-engaged patients. Tirzepatide 15 mg produced an additional 18.4% weight loss from the post-lead-in baseline, for a total of 26.2% from original baseline. [4]

SURMOUNT-4 (N=670) addressed the durability question directly. Patients who completed 36 weeks of tirzepatide were randomized to continue the drug or switch to placebo. After a further 52 weeks, the continuation group lost an additional 5.5% of body weight, while the withdrawal group regained 14.8%. [5] Weight returns when the drug stops. That finding shapes how long prescribers expect patients to stay on therapy.

Mounjaro vs. Wegovy vs. Ozempic: Direct Comparisons

No single randomized trial has put tirzepatide and semaglutide 2.4 mg (Wegovy) head-to-head in a weight-loss population. The comparison currently relies on cross-trial data and one diabetes-focused head-to-head, the SURPASS-2 trial (N=1,879), which showed tirzepatide 15 mg reduced HbA1c by 2.46% and body weight by 12.4% versus semaglutide 1 mg's 1.86% HbA1c reduction and 6.2% weight reduction. Semaglutide 1 mg (Ozempic's approved diabetes dose) is a lower dose than the 2.4 mg Wegovy formulation, so this comparison is not a clean surrogate.

From the individual trial benchmarks:

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961, adults without diabetes). [6] That trial, published in the New England Journal of Medicine in 2021, was the registration study for Wegovy's obesity approval.

In STEP-2 (N=1,210, adults with type 2 diabetes), semaglutide 2.4 mg produced 9.6% weight loss at 68 weeks versus 3.4% placebo. [7]

In STEP-8 (N=338), a direct head-to-head trial against liraglutide 3 mg (Saxenda), semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% for liraglutide at 68 weeks (P<0.001). [8] Saxenda was statistically inferior on every weight endpoint tested.

Comparing these figures side by side:

| Drug | Dose | Trial | Duration | Mean Weight Loss | |---|---|---|---|---| | Tirzepatide (Zepbound/Mounjaro) | 15 mg weekly | SURMOUNT-1 | 72 weeks | 20.9% | | Semaglutide (Wegovy) | 2.4 mg weekly | STEP-1 | 68 weeks | 14.9% | | Semaglutide (Ozempic) | 1 mg weekly | SURPASS-2 | 72 weeks | 6.2% | | Liraglutide (Saxenda) | 3 mg daily | STEP-8 | 68 weeks | 6.4% |

The table above reflects different trial populations and designs, so the numbers are not perfectly interchangeable. They do, however, reflect the consistent direction across the literature: tirzepatide produces numerically larger weight reductions than any approved GLP-1-only option.

The Cardiovascular Evidence Gap and SELECT Trial Context

Semaglutide 2.4 mg has a completed cardiovascular outcomes trial. The SELECT trial (N=17,604) enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide reduced major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 39.8 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). [9]

Tirzepatide does not yet have a completed cardiovascular outcomes trial in an obesity population. The SURMOUNT-MMO (major adverse cardiovascular events) trial is ongoing. Until those data are available, physicians prescribing for primary cardiovascular risk reduction may weigh the SELECT evidence in favor of semaglutide.

The American Association of Clinical Endocrinology (AACE) obesity clinical practice guidelines state that "anti-obesity medications should be considered as an adjunct to lifestyle therapy in patients with a BMI greater than 30 kg/m² or greater than 27 kg/m² with obesity-related comorbidities." [10] Neither tirzepatide nor semaglutide is named as universally preferred; drug selection depends on comorbidity profile, cost, insurance coverage, and patient preference.

Dosing, Titration, and Administration

Mounjaro and Zepbound share the same titration ladder because they contain the same molecule. The prescribing schedule begins at 2.5 mg once weekly for 4 weeks. The dose escalates by 2.5 mg every 4 weeks as tolerated, through maintenance doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

The 2.5 mg starting dose is a titration dose only, not a therapeutic dose. Most patients with diabetes reach a maintenance dose of 5 mg to 15 mg depending on glycemic response and tolerability. For weight management under the Zepbound label, the minimum recommended maintenance dose is 5 mg weekly after the first 4 weeks. [1]

Administration is subcutaneous injection into the abdomen, thigh, or upper arm. Patients rotate sites to reduce injection-site reactions. The auto-injector pen does not require reconstitution and can be stored at room temperature for up to 21 days.

Saxenda (liraglutide 3 mg) differs meaningfully here: it requires a daily injection with its own titration schedule over 5 weeks (starting at 0.6 mg daily). The once-weekly convenience of tirzepatide and semaglutide is an adherence advantage that once-daily dosing cannot match for most patients.

Side Effects and Contraindications

The most common adverse effects of tirzepatide are gastrointestinal. In SURMOUNT-1, nausea occurred in 31.0% of patients on 15 mg vs. 6.7% placebo, diarrhea in 22.1% vs. 10.0%, vomiting in 14.2% vs. 2.5%, and constipation in 12.1% vs. 3.4%. [2] Most events were mild to moderate and clustered around dose-escalation windows.

Serious adverse events to know:

• Thyroid C-cell tumors: Contraindicated in patients with personal or family history of MTC or MEN2. This is a class-level boxed warning shared with semaglutide and liraglutide. Evidence comes from rodent studies; human risk is not established but cannot be excluded.
• Pancreatitis: Discontinue if pancreatitis is suspected. Acute pancreatitis has been reported. Monitor patients with a history of pancreatitis carefully.
• Hypoglycemia: When used with insulin or insulin secretagogues (sulfonylureas), reduce the secretagogue dose to lower hypoglycemia risk.
• Oral contraceptive absorption: Tirzepatide slows gastric emptying and may reduce oral medication absorption transiently. The Zepbound label recommends switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after each dose escalation. [1]
• Diabetic retinopathy: Rapid improvement in glycemic control has been associated with worsening of diabetic retinopathy in some patients with pre-existing disease. This effect is also observed with other agents that lower HbA1c rapidly.

Semaglutide carries an essentially identical safety profile at the class level, with the same boxed thyroid warning. Liraglutide shares those warnings and additionally has data from SCALE trials showing a higher rate of gallbladder events compared to placebo.

Mounjaro vs. Ozempic: Same Class, Different Scope

Both Mounjaro (tirzepatide) and Ozempic (semaglutide 1 mg) are FDA-approved for type 2 diabetes. Ozempic is also approved to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease, an indication the SELECT trial now supports for Wegovy in obesity without diabetes.

The difference in mechanism is the key clinical distinction. Ozempic activates only GLP-1 receptors. Mounjaro activates both GLP-1 and GIP receptors. In the SURPASS-2 head-to-head trial (N=1,879 to 40 weeks), tirzepatide 15 mg beat semaglutide 1 mg on HbA1c reduction (2.46% vs. 1.86%) and weight loss (12.4% vs. 6.2%). Both differences were statistically significant (P<0.001). [11]

Neither drug replaces lifestyle changes. SURMOUNT-4's withdrawal data make clear that the weight returns after stopping. A patient who loses 20% of body weight on tirzepatide and then discontinues the drug can expect roughly 14.8% regain over 52 weeks without the drug. [5]

Who Is a Good Candidate for Mounjaro vs. Other Options?

A practical candidate-selection framework, reviewed by the HealthRX endocrinology team, sorts patients across four criteria:

1. Primary goal: glycemic control with weight benefit Consider Mounjaro (tirzepatide). It holds FDA approval for type 2 diabetes and consistently outperforms semaglutide 1 mg on both HbA1c and weight endpoints in head-to-head data.

2. Primary goal: weight loss without diabetes Consider Zepbound (tirzepatide) if maximum weight loss is the objective and insurance covers it. Consider Wegovy (semaglutide 2.4 mg) if cardiovascular risk reduction is also a priority and SELECT-level evidence is required by the prescriber or payer. Saxenda (liraglutide 3 mg) produces roughly 6% weight loss and requires daily injection; it remains an option when weekly injections are not acceptable to the patient or when cost is the determining factor.

3. Established cardiovascular disease without diabetes Wegovy (semaglutide 2.4 mg) has the SELECT cardiovascular outcomes data. Tirzepatide's cardiovascular outcomes trial is still running. Prescribers who require completed outcomes data for this population will likely choose semaglutide.

4. Cost and access constraints List prices in 2025 run approximately $1,069/month for Mounjaro and $1,349/month for Zepbound without insurance. Ozempic and Wegovy list prices are comparable. Saxenda's monthly cost at 3 mg daily can exceed $1,300. Manufacturer savings programs exist for commercially insured patients; Medicare Part D coverage under each brand varies by plan formulary. The AACE guidelines recommend discussing cost as a shared decision-making component before initiating any anti-obesity medication. [10]

Mounjaro During Weight Maintenance: What SURMOUNT-4 Tells Prescribers

Stopping Mounjaro or Zepbound is not like stopping a short-course antibiotic. SURMOUNT-4 randomized patients who had completed 36 weeks of tirzepatide (achieving approximately 20.9% weight loss) to either continue tirzepatide or switch to placebo for 52 more weeks. [5]

Continuation patients lost an additional 5.5% from their week-36 weight. Withdrawal patients regained 14.8% of baseline body weight by week 88. That regain occurred even though both groups received counseling on diet and physical activity throughout.

The JAMA authors concluded that "treatment with tirzepatide for 36 weeks resulted in substantial weight loss that was largely regained after treatment discontinuation." [5] This finding aligns with what the STEP-5 trial (N=304 to 104 weeks) showed for semaglutide: weight is maintained only for as long as the drug is taken, with progressive regain after stopping. [12]

For prescribers, this means tirzepatide and semaglutide are best framed as long-term therapies rather than 6-month courses, an important conversation to have before the first injection.

Practical Considerations: Storage, Injection Technique, and Missed Doses

Mounjaro auto-injector pens should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). A single pen may be kept at room temperature below 86°F (30°C) for up to 21 days. Do not freeze.

If a weekly dose is missed and the next scheduled dose is more than 4 days away, inject the missed dose as soon as possible. If the next scheduled dose is 3 days away or less, skip the missed dose and resume the regular schedule. Do not double-dose.

Injection-site reactions including erythema, pruritus, and induration occur in approximately 3% to 7% of patients. Rotating among three sites (abdomen, thigh, upper arm) and injecting at least 2 inches from the previous site minimizes local reactions.

Frequently Asked Questions